Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | CHRNB2 | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |
mRNA | KCNN1 | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |
mRNA | MSH6 | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |
mRNA | SUPT20H | CTRPv2 | pan-cancer | AAC | 0.13 | 5e-05 |
mRNA | PRKX | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |
mRNA | ELAVL3 | CTRPv2 | pan-cancer | AAC | 0.16 | 5e-05 |
mRNA | IGSF9B | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |
mRNA | TAF5L | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |
mRNA | RIMS3 | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |
mRNA | UNC80 | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |